|
SIGA Technologies is trying to put itself on the front lines of US biodefense efforts. The drug company has a number of development programs for vaccines, antivirals, and antibiotics for drug resistant infections; however, its main focus is on vaccines for bio-defense. The company's smallpox vaccine ST-246, which is intended both to prevent and treat the disease, has recieved Fast Track and Orphan Drug designations from the FDA. SIGA is also developing vaccines for use against hemorrhagic fevers and other infectious diseases and biothreats. Much of its work is done through funding from the National Institutes of Health.
|
| | | Contact Information | |
Address: |
420 Lexington Ave., Ste. 408
New York, NY 10170
| | Phone: | 212-672-9100 | | Fax: | 212-697-3130 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 8.10 M | | Revenue Growth (1 yr): | 20.40% | | Employees (2008): | 43 | | Employee Growth (1 yr): | 13.20% |
|
|
Key People
| | • |
Chairman and CEO:
Eric A. Rose
| | • |
Acting CFO and Secretary:
Ayelet Dugary
|
|
|
